Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-CD228A |
Synonyms | |
Therapy Description |
SGN-CD228A is an antibody-drug conjugate comprising a CD228 monoclonal antibody linked to eight molecules of the anti-microtubule compound MMAE, which delivers the cytotoxic agent to CD228-expressing tumor cells, potentially resulting in delayed tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2688). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-CD228A | SGNCD228A|SGN CD228A | SGN-CD228A is an antibody-drug conjugate comprising a CD228 monoclonal antibody linked to eight molecules of the anti-microtubule compound MMAE, which delivers the cytotoxic agent to CD228-expressing tumor cells, potentially resulting in delayed tumor growth (Cancer Res 2019;79(13 Suppl):Abstract nr 2688). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |